Rockefeller Capital Management
AVIR icon

Rockefeller Capital Management’s Atea Pharmaceuticals AVIR Stock Holding History

Rockefeller Capital Management’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$25.9K Buy
4,822
+3,882
+413% +$17.8K ﹤0.01% 3590
2025
Q4 		$3.36K Buy
+940
New +$2.99K ﹤0.01% 4185
2021
Q4 		– Sell
-3,000
Closed -$105K – 3761
2021
Q3 		$105K Hold
3,000
– – ﹤0.01% 1846
2021
Q2 		$64K Buy
+3,000
New +$90.1K ﹤0.01% 1966

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Rockefeller Capital Management's AVIR Position: Q1 2026 in Review

Rockefeller Capital Management increased its Atea Pharmaceuticals (AVIR) stake by 413% in Q1 2026, buying an estimated $17.8K and bringing the position to 4,822 shares worth $25.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3590.

Rockefeller Capital Management first reported a position in AVIR in Q2 2021 and has held it in 4 quarters since. The position peaked at $105K in Q3 2021. 127 funds tracked by Wall St. Rank hold AVIR as of Q1 2026.

  • Rockefeller Capital Management held 4,822 shares of Atea Pharmaceuticals worth $25.9K as of Q1 2026.
  • Rockefeller Capital Management bought 3,882 Atea Pharmaceuticals shares in Q1 2026, an estimated $17.8K.
  • Atea Pharmaceuticals made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q1 2026, its #3590 holding.
  • Rockefeller Capital Management first reported a position in Atea Pharmaceuticals in Q2 2021 and has held it in 4 quarters since.
  • Rockefeller Capital Management's Atea Pharmaceuticals position peaked at $105K in Q3 2021.
  • 127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.